{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:03:40Z","timestamp":1784192620302,"version":"3.55.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Enterobacter\ncloacae<\/jats:italic>\n            strains from hospitalized patients with a range of\ninfections were collected by 17 laboratories in the Asia-Pacific region\nand South Africa. Isolates for which ceftriaxone MICs were above 1\u03bc\ng\/ml and\/or ceftazidime MICs were above 2 \u03bcg\/ml, as\nwell as 46 strains for which ceftriaxone and\/or ceftazidime MICs were\nat or below these values, were screened for levels of extended-spectrum\u03b2\n-lactamase (ESBL) production through the use of broth\nmicrodilution for the detection of clavulanate enhancement of the\nactivity of ceftriaxone, ceftazidime, and cefepime. Of the isolates\nexamined, ceftriaxone and\/or ceftazidime had elevated MICs for\n44%, of which 36% were ESBL positive. ESBL-positive\nstrains were commonly susceptible to piperacillin-tazobactam and more\nfrequently resistant to several other antimicrobials studied. A\ncefepime MIC above 0.25 \u03bcg\/ml had the highest sensitivity\n(100%) and specificity (74%) for predicting the presence\nof an\nESBL.\n          <\/jats:p>","DOI":"10.1128\/aac.47.12.3989-3993.2003","type":"journal-article","created":{"date-parts":[[2003,11,24]],"date-time":"2003-11-24T22:53:35Z","timestamp":1069714415000},"page":"3989-3993","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["Prevalence of Extended-Spectrum \u03b2-Lactamase-Producing\n            <i>Enterobacter cloacae<\/i>\n            in the Asia-Pacific Region: Results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001"],"prefix":"10.1128","volume":"47","author":[{"given":"J. M.","family":"Bell","sequence":"first","affiliation":[{"name":"Microbiology and Infectious Diseases Department, Women's and Children's Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Turnidge","sequence":"additional","affiliation":[{"name":"Microbiology and Infectious Diseases Department, Women's and Children's Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. N.","family":"Jones","sequence":"additional","affiliation":[{"name":"The JONES Group\/JMI Laboratories, North Liberty, Iowa, and The Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SENTRY Asia-Pacific Participants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2269-2275.2001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1936-1942.2000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.7.2165-2169.1999"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.933-951.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1211"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.4.1237-1243.2002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.630-637.2002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2838"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.27.12.2887-2890.1989"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3177-3179.2000"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.4.441"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3239-3240.2000"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.1.175-182.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/32.4.595"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.330"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.1.65"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1577-1580.2002"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.557"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2184-2190.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.307"},{"key":"e_1_3_2_22_2","unstructured":"National\nCommittee for Clinical Laboratory Standards. 2000.\nMethods for dilution antimicrobial susceptibility tests for bacteria\nthat grow aerobically fifth ed. NCCLS document M7-A5. Approved\nstandard. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_23_2","unstructured":"National\nCommittee for Clinical Laboratory Standards. 2002.\nPerformance standards for antimicrobial susceptibility testing; 12th\ninformational supplement fifth ed. NCCLS document M100-S12. National\nCommittee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.1.76-79.1996"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200112000-00006"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.596"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2193"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.2.220"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.1999.5.189"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.2.542-546.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00255.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1098-1100.2002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.12.3989-3993.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.12.3989-3993.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:42:54Z","timestamp":1645465374000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.12.3989-3993.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1128\/AAC.47.12.3989-3993.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.12.3989-3993.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"2003-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}